Information  X 
Enter a valid email address

ABR INVESTMENTS DAC (IRSH)

  Print      Mail a friend

Thursday 28 March, 2019

ABR INVESTMENTS DAC

Declaration of Dividend Payment

RNS Number : 3661U
ABR INVESTMENTS (IRELAND) DAC
28 March 2019
 

Company Announcement

 

 

Company Name    ABR INVESTMENTS (IRELAND) DAC

Headline:  Increase of Note Principal Amount Outstanding

 

28th March, 2019

 

                                                                                                                                                     

 

 

 

 

 

ABR INVESTMENTS (IRELAND) DAC

 GBP 300,000,000 NOTE DUE 31 OCTOBER 2045 (ISIN: IE00BYR5CL08) (THE "NOTE")

 

The Directors of ABR Investments (Ireland) DAC (the "Issuer")"wish to announce that:-

 

·    Pursuant to Condition 5.1.1, 12th March, 2019 has been declared as an Interest Payment Date.

 

·    Pursuant to Condition 5.1.2 that an amount of USD$30,000,000.00 (the "Determined Amount") will be payable on the Interest Payment Date. 

 

·    Pursuant to Condition 5.1.2 the Determined Amount will be applied in the following order of priority:

 

·    in payment (and / or reimbursement) of all Expenses due and payable (which we have determined to be attributable to the Note); and

 

·    the balance to the Noteholder (whether as a payment of interest (or in respect of interest) on the Note or otherwise) (the "Payment").

 

·    Pursuant to Condition 5.3.6, the Payment will be paid to the Noteholder appearing in the Register as at the opening of business (local time in Dublin) on the Record Date. 

 

 

 

Enquiries:

 

The Directors

ABR Investments (Ireland) DAC

Telephone: +353 61 364 350

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 This announcement has been issued through the Companies Announcement Service of Euronext Dublin.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEJPMITMBTTBBL

a d v e r t i s e m e n t